Atopic dermatitis

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'

Retrieved on: 
Monday, March 18, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Growth, Atopic dermatitis, Inflammation, Patient, EASI, Technology transfer, PDE4, IND, Patent, FDA, Steroid, JAK, Pharmaceutical industry

Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.

Key Points: 
  • Shaperon, Inc. (Kosdaq: 378800), a biotechnology company developing innovative immune drugs, announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis.
  • Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026.
  • Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030.
  • Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

Akston Biosciences' AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Manufacturing, Diabetes, Health, Pharmaceutical, Research, Other Manufacturing, Infectious Diseases, Science, Veterinary, Clinical Trials, MERS, NOD, Atopic dermatitis, Insulin, Immune tolerance, CGMP, Epitope, Mouse, Immunoglobulin G, Chronic pain, Protein, Infection, Vaccination, Immune system, Nerve growth factor, Notifiable disease, Dengue fever, Vaccine

The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).

Key Points: 
  • The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).
  • AKS-107 is a human IgG1 Fc-fusion protein engineered to retain conformational insulin epitopes that bind to B cell receptors while preventing binding to the insulin metabolic receptor.
  • Regarding its Animal Health applications, Akston is partnered with Dechra Pharmaceuticals PLC to commercialize canine and feline ultra-long insulins.
  • Akston Biosciences Corporation is dedicated to accelerating the next revolution in Animal Health by inventing, developing, and manufacturing breakthrough protein therapeutics for veterinary use.

Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis

Retrieved on: 
Sunday, March 10, 2024
Health, Medical Devices, Other Health, Clinical Trials, Research, Science, Biotechnology, Dermatology Life Quality Index, Atopic dermatitis, Prurigo nodularis, Nemolizumab, Patient, Sleep, American Academy, Quality of life, European Medicines Agency, Skin, AAD, FDA, DLQI, IGA, Food, Pharmaceutical industry

Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.

Key Points: 
  • Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.
    build and strengthen for these debilitating diseases, where symptoms
    such as intense itch can put a significant burden on quality of life.
  • response in prurigo nodularis and atopic dermatitis, respectively.”
    69% of those who had received continuous nemolizumab treatment and 65% of nemolizumab-naïve patients had reached clearance or almost-clearance of skin lesions, as measured on the Investigator’s Global Assessment (IGA) score
    Sleep disturbance, as measured by the sleep disturbance numerical rating scale (SD-NRS), also continued to improve, as well as quality of life, as measured by the Dermatology Life Quality Index (DLQI).1
    Results also reinforced nemolizumab’s rapid onset of action, with nemolizumab-naïve patients rapidly achieving an at least four-point improvement in itch intensity, as measured by the PP-NRS, as early as week four, consistent with the continuous-nemolizumab cohort.
  • Nemolizumab was also granted U.S. FDA Priority Review for prurigo nodularis.
  • Further submissions to regulatory authorities in additional countries are planned in 2024.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JOSEPH F. MEROLA, MD, MMSc, FAAD, FACR

Retrieved on: 
Thursday, April 4, 2024
Cone Health Women's Hospital, Internal medicine, Patient, Skin, FAAD, Connective tissue, DSM-IV codes, Education, ASA, MDS, MMSc, Mass, Harvard Medical School, Associate, National Psoriasis Foundation, Psoriatic arthritis, Hospital, Public health, Atopic dermatitis, Dermatomyositis, Lupus, American Academy, Assessment, Management

NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
  • Distinguished Chair in Dermatology and is Professor at the Peter O'Donnell Jr. School of Public Health.
  • "We are proud to announce the addition of Dr. Joseph Merola to ASA's Board of Directors.
  • He was recently elected to the Board of the American Academy of Dermatology.

The Kinetix Group and Pfizer Health Equity Work Recognized by PM360

Retrieved on: 
Friday, March 29, 2024
Inflammation, Health, TKG, Atopic dermatitis, Pfizer, Health equity, Patient, Immunology, Unbranded, Multimedia, Marketing, Pharma, Nursing

NEW YORK, March 29, 2024 /PRNewswire/ -- The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative.

Key Points: 
  • NEW YORK, March 29, 2024 /PRNewswire/ -- The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative.
  • The Pfizer Inflammation and Immunology Strategic Customer Group originally developed the idea to address a gap in equitable patient and provider education resources surrounding atopic dermatitis.
  • "I am proud to be a part of a company like TKG, where there is a genuine commitment to addressing health equity and social determinants of health.
  • The Kinetix Group, a healthcare strategic advisory and marketing agency, is a part of Petauri.

NEW RESEARCH FINDS ADULTS, CHILDREN AND TEENS WITH ECZEMA EXPERIENCE SIGNIFICANT MENTAL HEALTH SYMPTOMS

Retrieved on: 
Wednesday, March 27, 2024
Research, Depression, Atopic dermatitis, Mental, Caregiver, Patient, CQD, Mental health, Child, Anxiety, Dermatitis, Flare, Pleasure, NEA, Emotion, Nursing

NOVATO, Calif., March 27, 2024 /PRNewswire/ -- The National Eczema Association (NEA) today announced the first publication from its real-world research on eczema and its impacts on mental health. The results were published in the journal Dermatitis in March 2024.

Key Points: 
  • In a new study, the NEA research team aimed to evaluate patient-reported mental health symptoms, their correlation with eczema severity, and patient-perceived associations of eczema and its impacts on mental health.
  • The survey included questions about eczema symptoms, mental health symptoms, perceptions of the connection between eczema and mental health, and experiences accessing mental health services.
  • The study findings illustrated that adults, children and teens with eczema experience a significant mental health burden that increases with eczema severity:
    70% of respondents reported that either their own or their child's mental health was impacted by eczema during the past year.
  • Those with more severe eczema symptoms were more likely to have 10+ days of poor mental health than those with less severe eczema symptoms.

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, SAN, Ulcerative colitis, Week, CDAI, B cell, Atopic dermatitis, BTLA, Q2, PD-1, Inflammation, Annual general meeting, AAD, UC, Idealized cognitive model, Rheumatoid arthritis, IGA, Patient, BDCA2, IND

“We will have a number of important events in 2024 including the top-line data readout of ANB032's Phase 2b trial in atopic dermatitis by year end,” adds Faga. “We also plan to move our third and fourth ICMs -- ANB033, our anti-CD122 antagonist, and ANB101 -- into the clinic this year, with IND filings planned for Q2 and H2, respectively.”

Key Points: 
  • “Enrollment is ongoing in three global Phase 2 trials for ANB032, our BTLA agonist, in atopic dermatitis and rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ulcerative colitis.
  • The decrease relates primarily to cash used for operating activities and the $50 million stock repurchase program.
  • The change is due primarily to increased royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022.
  • Acquired in-process research and development of $7.3 million for the three and twelve months ended December 31, 2023 related to the exclusive licensing agreement with Centessa Pharmaceuticals.